109113-97-5

Basic information

• Product Name: IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYL-
• Synonyms: IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYL-;6-CHLORO-2-(TRIFLUOROMETHYL)-IMIDAZO[1,2-B]PYRIDAZINE
• CAS NO: 109113-97-5
• Molecular Formula: C7H3ClF3N3
• Molecular Weight: 221.57
• Product Categories: Halides;Fused Ring Systems
• Mol File: 109113-97-5.mol

Chemical Properties

• Appearance: /
• Density: 1.68g/cm³
• Refractive Index: 1.59
• Storage Temp.: 2-8°C
• PKA: -0.53±0.30(Predicted)
• CAS DataBase Reference: IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYL-(109113-97-5)
• EPA Substance Registry System: IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYL-(109113-97-5)

Safety Data

• Hazardous Substances Data: 109113-97-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYLis used as a potential medication for various therapeutic applications due to its unique chemical structure and biological properties.
Used in Anticancer Applications:
In the field of oncology, IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYLis used as an anti-cancer agent. It has been studied for its potential to target and treat cancer cells, offering a new avenue for cancer therapy.
Used in Antiviral Applications:
IMIDAZO[1,2-B]PYRIDAZINE, 6-CHLORO-2-TRIFLUOROMETHYLis also used as an antiviral agent, leveraging its properties to combat viral infections and potentially leading to the development of new antiviral medications.
Used in Antibacterial Applications:
Furthermore, this compound is utilized in antibacterial research, where it may contribute to the creation of new antibiotics to address the growing issue of bacterial resistance.

InChI:InChI=1/C7H3ClF3N3/c8-5-1-2-6-12-4(7(9,10)11)3-14(6)13-5/h1-3H

Upstream product

• 5469-69-2 6-chloro-pyridazin-3-ylamine 
• 431-37-8 3-chloro-1,1,1-trifluoroacetone 
• 431-35-6 3-bromo-1,1,1-trifluoroacetone 

Downstream Products

• 109114-00-3 2-trifluoromethylimidazo<1,2-b>pyridazine 

Relevant articles and documents

Spiro Compounds As NPY Y5 Receptor Antagonists

The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;Z1 is H, C1-C4 alkyl or F;Z is CH2, CH(C1-C4 alkyl), C(C1-C4 alkyl)2 or a bond;A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH2)0-1R1;B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom;R1 is —(C1-C4)alkyl(C1-C4)alkoxy; or C3-C8 cycloalkyl; or R1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;X is OR2 or NR3R4;R2 is C1-C4 alkyl;R3 is hydrogen or together with R4 and the nitrogen form a 5-6 saturated membered ring;R4 is C3-C8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.

AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.